Literature DB >> 20516128

The tumor suppressor p53: from structures to drug discovery.

Andreas C Joerger1, Alan R Fersht.   

Abstract

Even 30 years after its discovery, the tumor suppressor protein p53 is still somewhat of an enigma. p53's intimate and multifaceted role in the cell cycle is mirrored in its equally complex structural biology that is being unraveled only slowly. Here, we discuss key structural aspects of p53 function and its inactivation by oncogenic mutations. Concerted action of folded and intrinsically disordered domains of the highly dynamic p53 protein provides binding promiscuity and specificity, allowing p53 to process a myriad of cellular signals to maintain the integrity of the human genome. Importantly, progress in elucidating the structural biology of p53 and its partner proteins has opened various avenues for structure-guided rescue of p53 function in tumors. These emerging anticancer strategies include targeting mutant-specific lesions on the surface of destabilized cancer mutants with small molecules and selective inhibition of p53's degradative pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516128      PMCID: PMC2869527          DOI: 10.1101/cshperspect.a000919

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  156 in total

1.  Identification of a novel p53 functional domain that is necessary for mediating apoptosis.

Authors:  J Zhu; W Zhou; J Jiang; X Chen
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

2.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain.

Authors:  M G Mateu; A R Fersht
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

3.  Conformational stability and activity of p73 require a second helix in the tetramerization domain.

Authors:  D Coutandin; F Löhr; F H Niesen; T Ikeya; T A Weber; B Schäfer; E M Zielonka; A N Bullock; A Yang; P Güntert; S Knapp; F McKeon; H D Ou; V Dötsch
Journal:  Cell Death Differ       Date:  2009-09-18       Impact factor: 15.828

4.  Crystal structure of the yeast MATalpha2/MCM1/DNA ternary complex.

Authors:  S Tan; T J Richmond
Journal:  Nature       Date:  1998-02-12       Impact factor: 49.962

5.  Binding and modulation of p53 by p300/CBP coactivators.

Authors:  N L Lill; S R Grossman; D Ginsberg; J DeCaprio; D M Livingston
Journal:  Nature       Date:  1997-06-19       Impact factor: 49.962

6.  The oligomerization domain of p53: crystal structure of the trigonal form.

Authors:  M Miller; J Lubkowski; J K Rao; A T Danishefsky; J G Omichinski; K Sakaguchi; H Sakamoto; E Appella; A M Gronenborn; G M Clore
Journal:  FEBS Lett       Date:  1996-12-09       Impact factor: 4.124

7.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

8.  Thermodynamic stability of wild-type and mutant p53 core domain.

Authors:  A N Bullock; J Henckel; B S DeDecker; C M Johnson; P V Nikolova; M R Proctor; D P Lane; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

9.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.

Authors:  R K Brachmann; K Yu; Y Eby; N P Pavletich; J D Boeke
Journal:  EMBO J       Date:  1998-04-01       Impact factor: 11.598

Review 10.  The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.

Authors:  Doriane Gouas; Hong Shi; Pierre Hainaut
Journal:  Cancer Lett       Date:  2009-04-18       Impact factor: 8.679

View more
  119 in total

1.  Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α.

Authors:  Robert D Kendig; Fumitake Kai; Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Invest       Date:  2017-04-13       Impact factor: 2.176

2.  Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.

Authors:  Joel L Kaar; Nicolas Basse; Andreas C Joerger; Elaine Stephens; Trevor J Rutherford; Alan R Fersht
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

3.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

4.  p53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer.

Authors:  Piotr T Filipczak; Shuguang Leng; Carmen S Tellez; Kieu C Do; Marcie J Grimes; Cynthia L Thomas; Stephanie R Walton-Filipczak; Maria A Picchi; Steven A Belinsky
Journal:  Cancer Res       Date:  2019-01-08       Impact factor: 12.701

5.  Protein aggregation: p53 succumbs to peer pressure.

Authors:  Mazin Magzoub; Andrew D Miranker
Journal:  Nat Chem Biol       Date:  2011-05       Impact factor: 15.040

6.  Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.

Authors:  Simon M Vogel; Matthias R Bauer; Andreas C Joerger; Rainer Wilcken; Tobias Brandt; Dmitry B Veprintsev; Trevor J Rutherford; Alan R Fersht; Frank M Boeckler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

7.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

8.  Microchip-Based Structure Determination of Disease-Relevant p53.

Authors:  Maria J Solares; G M Jonaid; William Y Luqiu; Yanping Liang; Madison C Evans; William J Dearnaley; Zhi Sheng; Deborah F Kelly
Journal:  Anal Chem       Date:  2020-10-30       Impact factor: 6.986

9.  How does inflammation drive mutagenesis in colorectal cancer?

Authors:  Chia Wei Hsu; Mark L Sowers; Willie Hsu; Eduardo Eyzaguirre; Suimin Qiu; Celia Chao; Charles P Mouton; Yuri Fofanov; Pomila Singh; Lawrence C Sowers
Journal:  Trends Cancer Res       Date:  2017

10.  A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.

Authors:  Adam F Odell; Luke R Odell; Jon M Askham; Hiba Alogheli; Sreenivasan Ponnambalam; Monica Hollstein
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.